LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of “Moderate Buy” by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $112.60.

A number of equities analysts have recently commented on LMAT shares. Barrington Research reaffirmed an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wells Fargo & Company increased their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Citizens Jmp raised their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the sale, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares of the company’s stock, valued at approximately $401,143. The trade was a 43.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 54,453 shares of company stock valued at $5,906,174. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LMAT. Handelsbanken Fonder AB purchased a new stake in shares of LeMaitre Vascular in the second quarter worth $806,000. Contravisory Investment Management Inc. purchased a new position in LeMaitre Vascular during the second quarter worth about $233,000. Pacer Advisors Inc. grew its position in LeMaitre Vascular by 45.7% during the first quarter. Pacer Advisors Inc. now owns 2,172 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 681 shares in the last quarter. Glenmede Trust Co. NA increased its stake in LeMaitre Vascular by 14.8% in the 1st quarter. Glenmede Trust Co. NA now owns 9,547 shares of the medical instruments supplier’s stock worth $1,042,000 after acquiring an additional 1,234 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in LeMaitre Vascular by 39.0% in the 1st quarter. Bank of America Corp DE now owns 180,095 shares of the medical instruments supplier’s stock worth $19,661,000 after acquiring an additional 50,497 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 2.4%

Shares of LeMaitre Vascular stock opened at $100.29 on Tuesday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The stock has a market capitalization of $2.29 billion, a P/E ratio of 37.01, a P/E/G ratio of 2.85 and a beta of 0.52. LeMaitre Vascular has a 52-week low of $79.00 and a 52-week high of $118.01. The stock’s 50-day simple moving average is $97.71 and its 200 day simple moving average is $98.06.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. During the same quarter in the previous year, the firm posted $0.48 earnings per share. The company’s quarterly revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, research analysts anticipate that LeMaitre Vascular will post 3 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st were given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.